Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis

Table 2 Association between chemoimmunotherapy and overall survival, by sex

Multivariable Analysis (n = 12,431)
	HR_adj^a (95% CI)
Chemoimmunotherapy Yes vs. No, Males	0.80 (0.74–0.87)
Chemoimmunotherapy Yes vs. No, Females	0.83 (0.76–0.90)
Immunotherapy*Sex	p = 0.6250
Propensity Matched Analysis (n = 3814; 1907 pairs)^a
	HR (95% CI)
Chemoimmunotherapy Yes vs. No, Males	0.80 (0.72–0.88)
Chemoimmunotherapy Yes vs. No, Females	0.88 (0.78–0.99)
Immunotherapy*Sex	p = 0.2162

^aadjusted for/ propensity matched on sex, age at diagnosis, histology (adenocarcinoma, squamous, large cell or other), race (white, Black or Asian/other), Charlson-Deyo comorbidity index, receipt of palliative radiation, year of diagnosis, insurance status (uninsured, privately insured, publically insured, unknown), and median household income for patient’s area of residence (< $38,000, $38,000–$47,999, $48,000–$62,999, >$63,000), * interaction effect
Abbreviations: HR Hazard Ratio, CI Confidence Interval

ISSN: 1471-2407